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Dimerisation of receptor-type protein tyrosine phosphatases (RPTPs) represents an appealing mechanism to regulate their enzymatic activity.
Studies thus far mostly concern the dimerisation behaviour of RPTPs possessing two tandemly oriented catalytic PTP domains. Mouse gene Ptprr
encodes four different protein isoforms (i.e. PTPBR7, PTP-SL and PTPPBSγ-42/37) that contain a single PTP domain. Using selective membrane
permeabilisation we here demonstrate that PTP-SL, like PTPBR7, is a single membrane-spanning RPTP. Furthermore, these two receptor-type
PTPs constitutively formed homo- and hetero-meric complexes as witnessed in chemical cross-linking and co-immunoprecipitation experiments,
in sharp contrast to the cytosolic PTPPBSγ-42 and PTPPBSγ-37 PTPRR isoforms. This multimerisation occurs independently of the PTP domain
and requires the transmembrane domain and/or the proximal hydrophobic region. Using overexpression of a PTPBR7 mutant that essentially lacks
the intracellular PTP domain-containing segment, a monomer-mimicking state was forced upon full-length PTPBR7 immunoprecipitates. This
resulted in a significant increase in the enzymatic activity of the PTPRR PTP domain, which strengthens the notion that multimerisation represents
a general mechanism to tone down RPTP catalytic activity.
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doi:10.1016/j.bbamcr.2007.10.023[1]. In contrast, for most receptor-type protein tyrosine phospha-
tases (RPTPs) the mechanisms controlling their enzymatic
activity remain to be disclosed [2]. Potential reversible mechan-
isms include PTP inactivation by reactive oxygen species,
through oxidation of the catalytic site cysteine [3], and
phosphorylation itself, as demonstrated by the increased activity
of PTP1B following its tyrosine-phosphorylation by the insulin
receptor [4]. Intracellular cleavage of RPTPs that results in the
release of the catalytic domain in the cytoplasm, on the other
hand, represents an irreversible way to abrogate dephosphoryla-
tion of membrane-associated substrates [5], and perhaps the
extracellular proteolytic cleavage or ectodomain ‘shedding’ that is
observed for multiple RPTPs should be added to this list [6–8].
The discovery of receptor-type PTPs led to the suggestion
that, in analogy with RTKs, these RPTPs may be regulated via
ligand-induced multimerisation [2]. Unfortunately, potential
ligand proteins have only been identified for a limited number
of RPTPs, and thus far ligand-dependent dimerisation and
Fig. 1. Characterisation of the α-SL-specific antiserum. A) Schematic representation of the different mouse PTPRR protein isoforms. Signal peptide (SP), hydrophobic
regions (HR1, HR2), kinase-interacting motif (KIM), catalytic phosphotyrosine phosphatase domain (PTP) and the segments recognised by the α-BR7 and α-SL-
specific antisera and the monoclonal antibody 6A6 are indicated. HR2 functions as a ‘stop-transfer signal’ in the receptor-type PTPBR7 isoform.Whether HR2 also is a
transmembrane-spanning region in PTP-SL has been addressed in the current study. B) Total lysates of HeLa cells transiently transfected with expression plasmids
pSG5/PTPBR7, pSG5/PTP-SL or pSG5/PTPPBSγ were analysed on Western blot using monoclonal antibody 6A6 (left panel) and rabbit polyclonal α-PTP-SL-
specific antiserum (right panel). Rabbit polyclonal α-BR7 antiserum only detected the PTPBR7 isoform (data not shown). Please note that the PTPPBSγmRNA codes
for both PTPPBSγ-42 and PTPPBSγ-37 by virtue of alternative translation start codons [21]. Molecular size markers are indicated on the left.
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[9,10]. Nevertheless, for multiple RPTPs, including CD45,
RPTPα and DEP-1, the artificial induction of dimerisation
clearly affected their enzymatic activity [11–13]. Intriguingly,
for quite a number of RPTPs it was found that they consti-
tutively form homo- and heterodimers in cells, presumably in
the absence of ligands [14,15]. Current knowledge about the
regulation of RPTP activity by dimerisation mostly comes from
studies on RPTPs that contain two tandemly oriented phos-
phatase domains; a catalytic, membrane-proximal domain (D1)
and a regulatory, membrane-distal domain (D2) [16]. Interac-
tions between these various PTP domains appeared key
determinants in the outcome regarding activity [15,17,18]. A
minority of RPTPs contains, like all non-transmembrane PTPs,
only a single phosphatase domain that is either active (DEP-1,
Glepp1, PTPBR7, PTPOST, RPTPβ, Sap-1, STEP61) or
inactive (IA2 and IA2β) [19]. Sap-1 was found to be able to
form dimers, but this is independent of its single catalytic PTP
domain and rather occurs through extracellular disulfide bond
formation. Intriguingly, this multimerisation led to a net de-
crease in activity [20].
PTPBR7 is one of the RPTPs with a single catalytic domain
but, in contrast to Sap-1, it does not contain extracellular
cysteines following cleavage of its signal peptide. In the current
study we investigated whether mouse PTPBR7 and its family
members PTP-SL, PTPPBSγ-42 and PTPPBSγ-37 also may be
regulated via multimerisation. These four PTPRR isoforms areFig. 2. PTP-SL is a transmembrane protein. A) HeLa cells selectively permeabilise
endogenous ER lumenal protein disulphide isomerase (left panels) or withα-Lamp-1 a
(right panels). B) HeLa cells expressing PTPBR7-VSV were permeabilised with the in
α-VSV antibody and rabbit α-BR7 antiserum. Anti-VSV staining always resulted in
apparatus (left panels), as for the α-BR7 antiserum on Triton X-100 permeabilised
present on the plasma membrane (upper middle panel), confirming that PTPBR7 is a
treated with the indicated detergents and then co-immunostained with monoclonal α-V
conditions α-VSV staining revealed Golgi and vesicular structures (left panels), whi
middle panel) is reduced to background levels (as observed in untransfected cells; arall encoded by a single-copy gene, Ptprr, but differ in their
amino-terminal sequence and, as a consequence, subcellular
localisation [21]. PTPBR7 is mainly localised on the plasma
membrane, PTPPBSγ-42 and PTPPBSγ-37 are in the cytosol,
and PTP-SL is distributed at vesicular structures and the Golgi
apparatus. All PTPRR isoforms can specifically bind to the
extracellular signal-regulated kinases 1 and 2 (ERK1/2) via a so-
called kinase-interacting motif (KIM), and in vitro [22] and in
vivo [23] studies established tyrosine-phosphorylated ERK1/2 as
bona fide PTPRR substrates. We now demonstrate that PTP-SL,
like PTPBR7, is a receptor-type PTP. PTPBR7 and PTP-SL, as
opposed to the cytosolic PTPPBSγ isoforms, were found to form
homo- and heterodimers constitutively. The multimerisation
attenuated PTPRR phosphatase activity, in favour of themodel in
which RPTP dimerisation negatively regulates PTP signalling.
2. Materials and methods
2.1. Expression constructs
Plasmids pSG5/PTPBR7, pSG8/PTPBR7-VSV, pSG8/PTP-SL-VSV [24],
pMyc-ERK2 [25] and pBICD1-HA [26] have been described elsewhere.
Plasmid pSG8/PTPBR7-C/S-VSV encoding a catalytically inactive Cys-to-Ser
mutant was generated by site-directed mutagenesis of Cys-578 (numbering
corresponds to amino acid position in PTPBR7; Acc. No. BAA06696) using the
QuickChange protocol (Stratagene, La Jolla, USA). Cloning of a SfiI–AgeI
fragment from pSG5/PTPPBSγ [21] into SfiI–AgeI digested pSG8/PTPBR7-
VSV generated the plasmid pSG8/PTPPBSγ-VSV. In these pSG8-based
constructs, a unique BglII restriction site in fact separates the PTPRR isoformd with digitonin or Triton X-100 were stained with α-PDI antiserum to detect
ntiserum to detect a cytosolic epitope in lysosome-associatedmembrane protein-1
dicated detergents and subsequently co-immunostained with mouse monoclonal
fluorescent signals at the plasma membrane, vesicular structures and the Golgi
cells (lower middle panel). In digitonin-treated cells α-BR7 reactivity was only
type-I transmembrane protein [24]. C) HeLa cells expressing PTP-SL-VSV were
SVantibody and rabbit α-PTP-SL-specific antiserum. For both permeabilisation
le the α-PTP-SL-specific signal as observed in Triton X-100 treated cells (lower
rowhead) in digitonin-treated cells.
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followed by a stop-codon was inserted in this BglII site for all variants, resulting
in plasmids encoding full-length HA-tagged PTPRR isoforms. PTPBR7 and
PTP-SL mutant expression constructs were generated by cloning a NotI digested
PCR fragment (spanning the amino acids as described in Figs. 4A and 5A) into
the pSG8-VSV vector [27]. Mutants lacking the hydrophobic region (HR) that
spans residues 128–154 in PTPBR7 and 7–33 in PTP-SL, respectively, were
generated by introducing a HindIII site on either side of the HR-encoding region
by site-directed mutagenesis. Subsequently, digestion with HindIII and religa-
tion of the plasmids resulted inΔHR deletion mutants. Plasmid pSG8/PTPBR7-
H-HAwas obtained by insertion of a primer duplex encoding a C-terminal HA-
tag into the unique NheI site of pSG8/PTPBR7-H-VSV. Expression constructs
generated by PCR were verified by sequence analysis.
2.2. Generation of PTP-SL-specific antiserum
To generate the polyclonal α-PTP-SL-specific antiserum a segment of
mouse PTP-SL cDNA encoding amino acids 32–105 (numbering according to
Acc. No. CAF06526) was obtained by PCR and cloned into pGEX-4T. The
resulting plasmid was introduced into E. coli strain DH5α and GST fusion
protein was induced and isolated as described [28]. Rabbits were immunised
with purified fusion protein following standards protocols. Resulting rabbit
polyclonal α-PTP-SL-specific antiserum was characterised on immunoblots of
lysates from transfected HeLa cells expressing individual full-length PTPRR
isoforms (see below). Blots were incubated simultaneously with rabbit
polyclonal α-PTP-SL-specific antiserum and mouse monoclonal antibody
6A6 [21] in a 1:5000 and 1:1000 dilution, respectively. Secondary antibodies
conjugated to fluorescent dyes were used for dual detection on an Odyssey
infrared imaging system (LI-COR) [29].
2.3. Cell culture
COS-1 (ATCC nr: CRL-1650) and HeLa cells (ATCC nr: CCL-2) were
cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco BRL,
Gaithersburg, MD) supplemented with 10% fetal calf serum (FCS) and grown in
a humidified atmosphere at 37 °C with 5% CO2. COS-1 cells were seeded at a
density of 750,000 (10-cm dish), 300,000 (6-cm dish) or 140,000 (6-well plate)
cells per well 1 day before being transiently transfected using DEAE-dextran
[25]. HeLa cells were seeded, at a density of 50,000 cells per well, on glass
coverslips in a 12-well plate 1 day prior to transient transfection using
polyethylene-imine (PEI, MW ∼25.000, Polysciences Inc.). In brief, for each
well 3.0 μl PEI (1 μg/μl) was added to a mixture of 50 μl Optimem (Gibco BRL)
and 1 μg DNA, and after immediately vortexing the transfection mixture was
incubated at RT for 10 min. Medium in the wells was replaced with 450 μl fresh
culture medium before addition of the transfection mixture to the cells. Two–
three hours later, 1 ml fresh culture medium was added to the cells and
incubation continued at 37 °C with 5% CO2. HeLa cells seeded in a 6-well plate
at a density of 150,000 cells per well were transfected with 9 μl PEI (1 μg/μl) in
a mixture of 150 μl Optimem and 3 μg of DNA as described above.
2.4. Chemical cross-linking
Transfected COS-1 cells in a 6-cm dish were washed three times with ice-
cold PBS and subjected to protein cross-linking for 1 h using BS3 (Pierce
Biotechnology, Rockford, USA) [30]. Cells were then washed twice with ice-
cold PBS and treated with 50 mM Tris–HCl in PBS to quench residual BS3.
Cells were harvested in 100 μl lysis buffer (50 mM Tris–HCl, pH 8.0; 150 mM
NaCl; 1% Triton X-100; 1 mM PMSF) supplemented with a protease inhibitor
cocktail (Roche Diagnostics GmbH, Mannheim, Germany) and incubated on ice
for 30 min. Lysates were cleared by centrifugation and subjected to SDS-PAGE.
Cross-linked proteins were detected by immunoblot analysis using monoclonal
antibody 6A6 [21].
2.5. Immunofluorescence microscopy
Twenty-four hours after transfection HeLa cells were washed once with PBS,
fixed for 30 min with 1% paraformaldehyde in 0.1 M PB buffer (61 mMNa2HPO4, 23 mM NaH2PO4, pH 7.4) and subsequently selectively permeabi-
lised according to Man et al. [31]. After blocking of specific sites with 10% FCS
in PBS, cells were incubated in PBS with a 1:200 dilution of mouse monoclonal
α-VSVantibody (P5D4) [32] and a 1:5000 dilution of either rabbit polyclonal α-
BR7 antiserum [8] or rabbit polyclonal α-PTP-SL-specific antiserum. Control
samples were incubated with a 1:100 dilution of rabbit α-PDI antiserum (#SPA-
890, StressGen Biotechnologies Corp.) or a 1:1000 dilution of rabbit α-Lamp-1
antiserum [33]. Following three washes with PBS, cells were incubated with
Alexa488-conjugated goat-anti-mouse and Alexa568-conjugated goat-anti-
rabbit antibodies (1:500 dilutions in PBS; Molecular probes). Following three
washes with PBS and methanol dehydration, coverslips were mounted on glass
slides using Mowiol (Sigma-Aldrich), and images were collected using confocal
laser scanning microscopy (MRC1024, Bio-rad).
2.6. Co-immunoprecipitation and immunoblot analyses
Transfected COS-1 cells on 10-cm dishes were washed with ice-cold PBS,
harvested in 500 μl lysis buffer and cleared by centrifugation as described above.
Supernatants were precleared with protein A-sepharose CL-4B beads (GE
Healthcare) before overnight incubation at 4 °C with beads preloaded with
mouse monoclonal α-HA antibody (12CA5) [34]. Beads were then washed six
times with ice-cold 1% Triton X-100 in PBS. Immunoprecipitated proteins were
taken up in sample buffer, subjected to SDS-PAGE and blotted onto PVDF
membranes by electrotransfer. Tagged proteins were detected using rabbit
polyclonal α-HA (sc-805, Santa Cruz Biotechnologies) and affinity-purified
rabbit polyclonal α-VSV (ITK Diagnostics BV) antibodies, diluted 1:1000 and
1:10,000 respectively. Immunoreactive bands were visualised as described [25].
2.7. Protein tyrosine phosphatase activity assays
COS-1 cells grown in 6-well plates were co-transfected with pMyc-ERK2
and pSG8/PTPBR7-VSV and/or pSG8/PTPBR7-T-VSV. Twenty-four hours
later cells were serum-deprived overnight. The next day cells were stimulated
with 20 ng/ml epidermal growth factor (EGF) for 5 min before being harvested
in ice-cold lysis buffer [29]. Total lysates were cleared by centrifugation and
Myc-ERK2 was immunoprecipitated from the lysates using monoclonal
antibody 9E10 [35]. Phospho-mycERK2 levels were determined by immunoblot
analysis as described previously [23].
Activity assays using the artificial substrate DifMUP (Invitrogen, Breda,
The Netherlands) were performed as follows. COS-1 cells grown in 10 cm
dishes were transfected with pSG8/PTPBR7-VSV and/or pSG8/PTPBR7-T-
VSVexpression constructs and 24 hours later cells were harvested and lysed as
described above. VSV-tagged full-length PTPBR7 was immunoprecipitated
from the lysates using monoclonal antibody 6A6 [21] and half of it was used for
quantitative immunoblot analysis on an Odyssey infrared imaging system (LI-
COR) using rabbit polyclonal α-VSV antiserum and goat-anti-rabbit secondary
antibody conjugated to AlexaFluor 680 (Molecular Probes, Eugene, OR, USA).
The remaining half of the PTPBR7-VSV-containing beads was washed once
with assay buffer (50 mM Hepes pH 7.2; 1 mM DTT; 0.1% BSA) before being
taken up in 100 μl assay buffer. Reactions were initiated by addition of 100 μl
assay buffer containing 200 μM DifMUP, and fluorescence emission by the
hydrolysed product (DifMUP) was recorded at 460 nm on a Wallac Victor 2
fluorescence plate reader (Perkin Elmer) at regular intervals over a 3 h time
period. Finally, the relative PTP activity (arbitrary units) was calculated for each
sample by taking the slope of the linear, steady state part of the fluorescence-
over-time curves and subsequently correcting for the amount of immunopre-
cipitated PTPBR7-VSV protein.
Determination of the normalised PTP activities of C-terminally VSV-tagged
PTPPBSγ, wild-type and catalytically inactive PTPBR7 was done as described
above, except that proteins were immunopurified using anti-VSV-G monoclonal
antibody P5D4 and subsequently released from the beads by a 30 min incubation
at 4 °C in the presence of an excess VSV-G epitope peptide (15 μg/ml; Sigma-
Aldrich). Resulting supernatant was subsequently used in activity assays and for
immunoblot analyses.
Statistical analyses of the relative PTP activity for PTPBR7 with and without
PTPBR7-T (n=3) and for PTPBR7 versus PTPPBSγ (n=4) involved Student's
t-test.
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3.1. PTP-SL is a transmembrane protein
Although PTP-SL contains an N-terminal signal peptide-like
sequence [36], thiswas shown to be non-functional [24], leaving its
membrane topology rather enigmatic. Therefore, before embarking
upon the associative capacities of the PTPRR isoforms, we first
determinedwhether PTP-SL should be regarded as transmembraneFig. 3. Homo- and heteromultimerisation of PTPRR isoforms. A) Intact COS-1 cells
BS3 crosslinker, and lysed. Cleared lysates were subjected to 6% SDS-PAGE and im
with an arrow, dimers with a filled arrowhead and multimers with an open arrowhead.
the proteins used in the co-immunoprecipitation experiments depicted in C). Coiled-c
domain (TM), kinase-interacting motif (KIM), catalytic domain (PTP) and the C-term
transfected with HA- or VSV-tagged PTPRR expression plasmids in the indicated co
lysates (CL) using monoclonal antibody 12CA5 (monoHA), co-precipitating protein
procedure was verified on separate immunoblots using a polyclonal anti-HA antiserPTP. To this end, we generated a rabbit polyclonal antiserum
directed against PTP-SL residues in between the two hydrophobic
stretches (Fig. 1A). Specificity of this α-PTP-SL-specific antibody
was demonstrated on Western blots using total lysates from
transfected HeLa cells expressing the various PTPRR isoforms.
Only the two largest PTPRR isoforms, PTPBR7 and PTP-SL, are
detected by the α-PTP-SL-specific antiserum (Fig. 1B).
We then used this antiserum in an indirect cytoimmuno-
fluorescence assay with selective membrane permeabilisationtransiently transfected with pSG5/PTPBR7 were treated with (+) or without (−)
munoblotted using monoclonal antibody 6A6. PTPBR7 monomers are indicated
Molecular size markers are indicated on the right. B) Schematic representation of
oil domains (CC), signal peptide (SP), hydrophobic region (HR), transmembrane
inal HA or VSVepitope tags (E) are indicated. C) COS-1 cells were transiently
mbinations. Upon immunoprecipitation (IP) of HA-tagged proteins from cleared
s were detected using polyclonal α-VSV antibody on immunoblots (IB). The IP
um.
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the lumenal ER marker protein disulphide isomerase (α-PDI)
[37] or against the cytosolic part of the lysosomes-associated
membrane protein-1 (α-Lamp-1) [33] confirmed that Triton X-
100 permeabilised all cellular membranes, whereas digitonin
only permeated the plasma membrane (Fig. 2). PTP-SL-VSV-
expressing HeLa cells that were treated with digitonin displayed
α-VSV antibody reactivity at the Golgi apparatus and vesicular
structures. Use of the α-PTP-SL-specific antiserum, however,
resulted in a similar staining pattern only when cells wereFig. 4. Mapping of the multimerisation domains in PTPBR7. A) Schematic representa
depicted in B). Nomenclature, encompassed or deleted (Δ) amino acid regions, and
domain (TM), kinase-interacting motif (KIM), catalytic domain (PTP) and C-termi
epitope-tagged BICD1, PTP-SL and PTPPBSγ proteins were given in Fig. 3B. B) T
tagged proteins were lysed (CL). Upon immunoprecipitation of HA-tagged protein
antiserum (IB: polyHA; upper panels), co-precipitating proteins were detected using
(data not shown) PTPBR7-T-ΔHR-VSVwas co-precipitating with full-length HA-tag
served as negative control. Background signals due to non-specific binding of PT
indicated for each panel on the left.treated with Triton X-100 (Fig. 2C). These data are in line with a
single-pass transmembrane topology for PTP-SL in which the
N-terminus resides at the lumenal side and the C-terminal part,
that contains the KIM and PTP domain, is in the cytosol.
3.2. PTPBR7 and PTP-SL form multimers
To determine whether PTPBR7 forms multimers on the cell
surface, the non-cell permeable chemical cross-linker BS3 was
used on transfected COS-1 cells expressing PTPBR7. Cross-tion of mutant PTPBR7 proteins used in the co-immunoprecipitation experiments
the position of signal peptide (SP), hydrophobic region (HR), transmembrane
nal epitope tag (E) are indicated for each mutant. Schematic representations of
ransfected COS-1 cells expressing the indicated combinations of HA- or VSV-
s (IP: monoHA; upper panels), which was verified using a polyclonal anti-HA
poly α-VSV antiserum (IB: polyVSV; lowest panels). In a parallel experiment
ged PTPBR7 and PTP-SL but not with HA-tagged PTPPBSγ and BICD1, which
PBR7-H-ΔHR-VSV are indicated by an asterisk. Molecular size markers are
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not considered because these do not localise on the cell surface
[21]. Immunoblot analyses revealed that not only monomeric
PTPBR7 but also species at the expected size of PTPBR7 dimers
and higher order multimers, that may represent complexes
between PTPBR7 and other proteins, were detectable following
BS3 treatment (Fig. 3A). To investigate whether PTPBR7 may
indeed homodimerise and perhaps can form hetero-meric
complexes with other PTPRR isoforms, immunoprecipitationFig. 5. PTPRR binding domains in PTP-SL. A) Schematic representation of mutant
encompassed or deleted (Δ) amino acid regions, and the position of hydrophobic regi
domain (PTP) and C-terminal epitope tags (E) are indicated. Schematic representat
Figs. 4A and 3B, respectively. B) COS-1 cells ectopically expressing the indicated HA
tagged proteins (IP: monoHA), which was verified on blot using polyclonal anti-HA
using polyclonal α-VSVantiserum (IB: polyVSV; lower panels). Specific and backgr
protein served as a negative control. Molecular size markers are indicated on the lefexperiments were performed on cell lysates containing PTPRR
isoforms that were differentially tagged at their C-terminus
(Fig. 3B). Intriguingly, VSV-tagged PTPBR7 co-precipitated
with HA-tagged PTPBR7 and PTP-SL, both transmembrane
proteins, but not with the cytosolic PTPPBSγ species (Fig. 3C,
left panels). Similarly, PTP-SL-VSV did not associate with HA-
tagged PTPPBSγ but was efficiently precipitated by the HA-
tagged transmembrane isoforms (Fig. 3C, middle panels). In
fact, the cytosolic PTPPBSγ-42/37 did not display any homo- orPTP-SL proteins used in co-immunoprecipitation experiments. Nomenclature,
on (HR), transmembrane domain (TM), kinase-interacting motif (KIM), catalytic
ions of epitope-tagged PTPBR7 mutants and PTPPBSγ proteins were given in
- and VSV-tagged proteins were lysed (CL). Upon immunoprecipitation of HA-
antiserum (IB: polyHA; upper panels), co-precipitating proteins were detected
ound signals are indicated by arrowheads and asterisks, respectively. The BICD1
t.
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implying that PTPRR KIM and PTP domains do not suffice for
this interaction.
3.3. PTPRR hydrophobic regions are required for
multimerisation
To examinewhich protein parts are mediating the association,
various epitope-tagged PTPBR7 deletion mutants (Fig. 4A)
were tested for their ability to co-precipitate with full-length
PTPBR7 and PTP-SL. Subcellular localisation of the various
mutants wasmonitored by immunofluorescencemicroscopy and
their potential secretion into the medium was tested through
immunoprecipitation and Western blotting using culture super-Fig. 6. Protein tyrosine phosphatase activity is reduced upon multimerisation. A) Tran
PTPBR7-T-VSV were serum-starved overnight, stimulated with EGF and subsequent
phosphorylated (IB: pERK1/2) and total (IB: polyMyc) Myc-ERK2 protein levels upo
immunoblot analysis. B) Quantitative representation of relative Myc-ERK2 phospho
(n=3, ⁎pb0.005, ⁎⁎pb0.045). C) Lysates from COS-1 cells expressing PTPBR7-V
antibody 6A6. Protein amounts in the cleared lysate (CL) and the immunoprecipita
(IB: polyVSV). D) Immunoprecipitates described in C) were used in a fluorescent in
state enzymatic activities measured for the given protein combinations were normalis
for precipitates from cells solely transfected with the PTPBR7-T-VSVexpression con
E) Lysates from COS-1 cells expressing PTPBR7-VSV, PTPPBSγ-VSV or PTPB
antibody against the VSV-G epitope tag. Proteins were released from the beads usin
activity measurements. Enzymatic activities were normalised for PTP protein contennatant (data not shown). Deletion of 353 (PTPBR7-T-VSV) or
466 (PTPBR7-H-VSV) C-terminal residues did not affect the
associative capacity (Fig. 4B), even though the PTPBR7-H-
VSVmutant had lost the transmembrane location and to a large
extent was now secreted into the culture medium [24]. To
assess a possible contribution of the hydrophobic region
(HR) that is contained within residues 128–154 in PTPBR7 and
7–33 in PTP-SL, respectively, we deleted this part in the above
mutants and tested the resulting proteins for binding to full-
length PTPRR isoforms. Mutant PTPBR7-T-ΔHR-VSV did
not reach the cell surface and resided predominantly in the
Golgi area but still it co-precipitated with PTPBR7 and PTP-
SL, and not with PTPPBSγ-42/37 (data not shown). Mutant
PTPBR7-H-ΔHR-VSV, however, lost this capability (Fig. 4B,sfected COS-1 cells expressing Myc-ERK2 together with PTPBR7-VSVand/or
ly lysed. VSV-tagged protein levels (IB: polyVSV) in the cleared lysate (CL) and
n immunoprecipitation using antibody 9E10 (IP: monoMyc) were determined by
rylation levels as determined in A). Results are presented as mean values±SEM
SV and/or PTPBR7-T-VSV were subjected to immunoprecipitation (IP) using
te were quantified by immunoblot analysis using polyclonal α-VSV antiserum
vitro phosphatase activity assay exploiting DifMUP as a substrate. The steady
ed for the amount of precipitated PTPBR7-VSV, with the exception of the values
struct (BR7-T). Results (n=3) are presented as mean values±SEM (⁎pb0.009).
R7-C/S-VSV were subjected to immunoprecipitation (IP) using a monoclonal
g VSV-G peptide and analysed on immunoblots and in fluorescent phosphatase
t. Results (n=4) are presented as mean values±SEM (⁎pb0.002).
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was not secreted by the cells (data not shown). This suggests
that either one of the hydrophobic regions is necessary for
PTPRR multimerisation.
To substantiate this, we also examined the multimerisation
ability of PTP-SL deletion mutants (Fig. 5A). Again, deletion of
353 C-terminal residues (PTP-SL-T-VSV) did not influence the
subcellular location or the interaction with PTPBR7 and PTP-
SL (Fig. 5B and data not shown). However, further deletion of
the transmembrane (TM) segment, leaving essentially the first
hydrophobic segment (PTP-SL-H-VSV), abrogated all interac-
tions with full-length PTPRR isoforms (Fig. 5B, left panels).
This is explained by the fact that this mutant localised at the
cytosolic side of vesicular structures, as determined using the
selective membrane permeabilisation protocol (data not shown).
Importantly, removal of the HR region from PTP-SL-T-VSV
still allowed multimerisation with PTPBR7 and PTP-SL (PTP-
SL-T-ΔHR-VSV; Fig. 5B, middle panels), underscoring the
importance of a proper membrane topology for the interaction.
Finally, we tested whether the segment containing the lu-
menal HR in PTPBR7 and PTP-SL can mediate multimerisation
on its own, without one of the partners being membrane-
anchored, by performing immunoprecipitation experiments with
cells co-expressing VSV- and HA-tagged PTPBR7-H (Fig. 5B,
right panels). The differentially tagged PTPBR7-H mutants
indeed were found to dimerise, corroborating that homo- and
heterodimerisation of transmembrane PTPRR isoforms requires
sequences encompassing the hydrophobic region and/or the
transmembrane segment.
3.4. Influence of multimerisation on PTPRR activity
To investigate whether PTPRR phosphatase activity is
regulated via multimerisation we hypothesised that a hetero-
dimer consisting of the full-length PTPBR7 and the mutant that
lacks the KIM and PTP domain, PTPBR7-T, would mimick an
RPTP monomeric state. Changes in PTPBR7 specific activity
upon co-expression of PTPBR7-T might thus be reflected in the
phosphorylation levels of co-transfected myc-tagged ERK2
following epidermal growth factor (EGF) stimulation of COS-1
cells. As expected, PTPBR7 expression resulted in reduced
Myc-ERK2 phosphorylation levels as compared to mock-
transfected cells (Fig. 6A and B). Co-expression of PTPBR7
with an excess of PTPBR7-T further reduced these phospho-
ERK levels. However, ectopic expression of PTPBR7-T alone
unexpectedly reduced Myc-ERK2 phosphorylation levels as
well. COS-1 cells do not express PTPRR isoforms endogen-
ously, so we assumed that PTPBR7-T influenced the activity of
other, endogenous proteins involved in the control of EGF
signalling. This prompted us to determine the enzymatic activity
in a more direct way, exploiting difluoromethylumbelliferyl
phosphate (DifMUP) [38] as an artificial substrate on PTPBR7
multimers as compared to monomer-mimicking PTPBR7—
PTPBR7-T complexes that were immunopurified from trans-
fected COS-1 cells. Applying monoclonal antibody 6A6,
directed against amino acids 348–413 of PTPBR7 that are
absent in PTPBR7-T-VSV, the five-fold excess of PTPBR7-T-VSV over PTPBR7-VSV in the lysates led to immunoprecipi-
tates that contained a ‘BR7-over-T’ ratio of 2.13:1 (Fig. 6C).
Upon normalisation for the amount of precipitated PTPBR7-
VSV this mixture (of PTPBR7/PTPBR7-T heterodimers and
homodimerised or monomeric PTPBR7) displayed a specific
activity that was significantly greater than that of PTPBR7
precipitates (Fig. 6D; pb0.009). This is in line with a model in
which enzymatic activity is increased upon dissolution of
multimers of transmembrane PTPRR isoforms. To corroborate
this finding, we compared the in vitro phosphatase activities of
the constitutively dimerising PTPBR7 and the exclusively
monomeric PTPPBSγ isoforms, again using DifMUP as a
substrate. Indeed, the normalised activity of the PTPRR mono-
meric isoforms was two-fold greater than that of the dimerising
receptor-type isoform (Fig. 6E; pb0.002). Taken together, our
results point to an attenuated enzymatic activity of the phos-
phatase domain in the constitutive multimers of transmembrane
PTPRR isoforms.
4. Discussion
In this study the concept of dimerisation as a regulatory
mechanism for RPTP activity was tested for the mouse PTPRR
isoform family. Generation of a dedicated antiserum in
conjunction with selective membrane permeabilisation enabled
us to show that PTP-SL, like PTPBR7, is a transmembrane-
spanning protein. These two RPTP isoforms formed homo- and
hetero-meric complexes, for which either the hydrophobic
segment or the transmembrane region is required. Unfortu-
nately, an effect of the PTPBR7 multimerisation status on its
catalytic activity towards the physiological substrate ERK1/2
could not be properly assessed. An in vitro assay exploiting a
small-molecule artificial substrate, however, indicated a sig-
nificant reduction in PTP activity upon multimerisation, in line
with current models for the regulation of other RPTPs.
Originally we predicted PTP-SL to be a type-I transmem-
brane protein based on the presence of two hydrophobic regions
in its N-terminal part [36]. However, the first did not function as
signal peptide, suggesting PTP-SL to be a membrane-associated
protein [24]. Also in the current study a mutant essentially
consisting of the HR segment, PTP-SL-H, was not able to cross
the membrane. The HR also did not serve as transmembrane
anchor since the PTPBR7-H mutant was secreted into the
medium. Our cell permeabilisation experiments now show that
the N-terminal part of PTP-SL is located in the lumen of
vesicular structures and the Golgi apparatus, whereas the C-
terminal part is found at the cytosolic side, demonstrating that
PTP-SL is a transmembrane protein. Unlike for PTPBR7, which
is a classical type-I transmembrane protein that is co-trans-
lationally targeted to the ER by a cleavable signal peptide and
anchored in the lipid bilayer by a ‘stop-transfer’ transmembrane
domain, the N-terminus of PTP-SL that includes the HR is
probably post-translationally translocated over the intracellular
membrane. The TM domain would then serve as signal-anchor
sequence to initiate translocation, defining PTP-SL to be a
‘type-I transmembrane protein without cleaved signal’ or ‘type-
III’ transmembrane protein [39].
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the above translocation process but rather serves a role in
dimerisation. Furthermore, it is required for the proper sub-
cellular localisation of the two receptor-type PTPRR isoforms.
PTPBR7 is predominantly expressed at the plasma membrane,
whereas PTP-SL is localised exclusively on intracellular
vesicles and the Golgi apparatus [21,25]. Although in vivo
PTPBR7/PTP-SL heterodimers most likely do not exist in view
of the distinct spatiotemporal expression patterns of PTPBR7
and PTP-SL [24], co-transfection studies demonstrated an
overlapping subcellular localisation in the Golgi area and at
late endosomal vesicles (data not shown). Surprisingly, deletion
of the HR sequence essentially swapped their localisation
patterns. PTP-SL-T-ΔHR-VSV was found also at the plasma
membrane, whereas PTPBR7-T-ΔHR-VSV no longer appeared
at the cell surface. It remains as yet unclear how the HR on the
one hand can facilitate intracellular retention of PTP-SL and on
the other hand is absolutely required for proper cell surface
routing of PTPBR7. This is even more puzzling knowing that
PTPBR7 is subject to N-terminal proteolytic processing at the
plasma membrane which renders a cleaved form, PTPRR-65,
that structurally resembles PTP-SL but remains localised at the
cell surface [8].
For many RPTPs the capacity to form homo- and
heterodimers has been documented. Surprisingly, the protein
domains that mediate the binding differ considerably between
subfamilies. First examples of RPTP dimerisation reflected the
homotypic association of RPTP type IIB extracellular segments
on opposing cells [40]. Crystallographic studies on RPTPα
triggered the notion that PTP domains themselves can also
dimerise, and as a result a so-called ‘wedge structure’ in the one
molecule blocks the catalytic activity of the other [17]. Many
examples of PTP domain— PTP domain interactions have now
been reported, including intra-molecular ones [41]. Contrary to
most RPTPs, PTPBR7 and PTP-SL contain a single phospha-
tase domain, excluding regulation of activity via intra-molecular
interactions between tandem PTP domains. Moreover, struc-
tural and chromatographic data indicated that the PTPRR
phosphatase domain behaves as a monomer [42], in line with
our finding that the cytosolic PTPPBSγ's do not multimerise.
Also the single PTP-like domains of IA-2 and IA-2β did not
associate with the PTPRR PTP segment [15]. For multiple
RPTPs the TM region was found to mediate both homotypic
and heterotypic interactions [14,43,44], and in the case of
RPTPα and CD45 the weak dimerisation potential displayed by
their ectodomains may well add to this [14,43]. In a comparative
study the homodimerisation capacity of the PTPRR TM
appeared weaker than that of the RPTPα and CD45 TM [44],
perhaps explaining why in PTPBR7 and PTP-SL the dimerisa-
tion potential of the HR-containing segment is also exploited.
The KIM domain in the PTPRR proteins enables their
association with several different mitogen-activated protein
kinases (MAPKs), including ERK1 and ERK2, which leads to
inactivation of the MAPK through dephosphorylation of their
regulatory tyrosine residue [22,45]. In line with this, signifi-
cantly elevated levels of phosphorylated ERK are found in
PTPRR deficient mouse brains [23]. In the rat phaeochromocy-toma cell line PC12, however, PTPRR isoforms were found to be
dispensable for ERK-dependent signalling, probably because
the regulatory serine residue in the KIM domain is constitutively
phosphorylated in these cells [29], thereby preventing KIM-
dependent binding of the MAPKs [46,47]. In the current study,
ectopic expression of PTPBR7 clearly reduced the phosphoryla-
tion levels of endogenous (data not shown) and ectopically
expressed ERK in EGF-stimulated cells. However, our attempts
to alter PTPBR7's specific activity towards ERK by over-
expression of a PTPBR7 mutant that lacks the KIM and PTP
domains (PTPBR7-T), which by dimerising with the wild-type
protein should mimick an increase in monomeric PTPBR7 in the
cell, could not be interpreted due to unexpected effects of the
PTPBR7-T mutant itself. The latter may be explained by the
capacity of PTPBR7-T to bind to other, endogenous RPTPs
(YN, unpublished), perhaps thereby altering their activity. In our
in vitro phosphatase assays using PTPBR7-T immunoprecipi-
tates, however, no significant contribution of co-purifying COS
cell-endogenous PTPs was apparent, leaving the PTPBR7-T
effect on ERK phosphorylation as yet enigmatic.
The notion that PTPBR7:PTPBR7-T heterodimers were
consistently formed during the above experiments allowed us to
measure PTP activity of immunopurified complexes in a direct
way using the artificial substrate DifMUP. This disclosed a
significant difference in normalised relative activity (79.03±
0.84 versus 89.93±2.06; arbitrary units) between PTPBR7
and PTPBR7:PTPBR7-T immuno-complexes. Because the
PTPBR7:PTPBR7-T precipitate still contained a two-fold
excess of PTPBR7, its normalised activity is in fact confounded
by the portion of PTPBR7 homodimers and possibly mono-
mers. Direct comparison of enzymatic activities of dimerising
(PTPBR7) and monomeric (PTPPBSγ) isoforms also revealed a
significantly greater activity for PTPRR monomers. Since con-
ceptually an on/off-type of regulation by dimerisation is the
most straightforward, the residual activity measured in the
PTPBR7 samples would be explained by assuming that about
half of the PTPBR7 subunits remained monomeric.
In conclusion, our data add further proof to a model in which
RPTP dimerisation results in the attenuation of its enzymatic
activity. Oxidation-induced Sap-1 dimerisation resulted in
reduced catalytic activity [20], whereas antibody-induced
oligomerisation of DEP-1 was shown to increase activity [13].
Upon treatment of cells with H2O2 we noted that PTPBR7
multimerisation was increased in a dose-dependent manner
(YN, unpublished) as was observed for RPTPα [48]. Putative
ligands for PTPBR7 (and PTP-SL for that matter) still remain to
be identified. Together with the mapping of additional PTPRR
substrates this ultimately will allow the assessment of the effect
of multimerisation on PTPRR activity in a more physiological
setting.
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